Status:

COMPLETED

Deferred Versus Fresh Embryo Transfers

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Infertility, Female

Eligibility:

FEMALE

18-40 years

Phase:

NA

Brief Summary

Controlled ovarian stimulation (COS) enhances the efficacy of ART (Assisted reproductive technology) by permitting multiple-oocyte yields, but also alters endometrial receptivity (ER) by an advancemen...

Detailed Description

Controlled ovarian stimulation (COS) enhances the efficacy of ART (Assisted reproductive technology) by permitting multiple-oocyte yields, but also alters endometrial receptivity (ER) by an advancemen...

Eligibility Criteria

Inclusion

  • Women \[18 - 40\[years of age (according to date of birth at time of informed consent) who are eligible for ovarian stimulation and ART treatment, including intracytoplasmic sperm injection (ICSI)
  • Absence of anatomical abnormalities of the reproductive tract that would interfere with implantation or pregnancy
  • Absence of any medical condition in which pregnancy is contraindicated
  • Motile, ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed). Intracytoplasmic sperm injection (ICSI) will be allowed during this trial
  • Body mass index 18 to 35 kg/m2, inclusive
  • Able to understand the study
  • Affiliation with a social security scheme
  • Dated and signed inform consent

Exclusion

  • Altered ovarian reserve (Day3: FSH \>12 UI/l; AMH\<1,0 ng/ml; AFC\<8)
  • History or presence of tumours of the hypothalamus or pituitary gland
  • Presence of non isolated uni- or bilateral hydrosalpinx
  • Abnormal gynaecological bleeding of undetermined origin
  • Contraindication to being pregnant and/or carrying a pregnancy to term
  • Known infection with human immunodeficiency virus, active hepatitis B or C virus in the female or male partner
  • History or presence of ovarian, uterine or mammary cancer
  • Known allergy or hypersensitivity to human gonadotropin preparations or to compounds that are structurally similar to any of the other medications administered during the trial
  • Substance abuse that would interfere with trial conduct, as determined by the investigator
  • Use of testicular or epididymal sperm
  • Pregnant patient, nursing patient
  • Participation in another ART clinical trial within the past 30 days
  • Women who have risk to develop severe ovarian hyperstimulation syndrome (OHSS) during controlled ovarian stimulation (COS) defined as ≥ 18 follicles measuring 10 - 14 mm on the day of triggering
  • Women with less than 3 follicles ≥ 15 mm on the triggering day or the day before the triggering
  • Women with premature progesterone elevation during COS ( ≥1.5 ng/ml)
  • Women with uterine polyps diagnosed during COS
  • Participation with another interventional study involving human subjects

Key Trial Info

Start Date :

September 24 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 31 2022

Estimated Enrollment :

237 Patients enrolled

Trial Details

Trial ID

NCT03349905

Start Date

September 24 2018

End Date

March 31 2022

Last Update

October 25 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hôpital Cochin

Paris, France, 75014